CANTON, MA, United States, via eTeligis Inc., 06/05/2014 - - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of two scientific posters at the 2014 International Conference on Opioids (ICOO), held in Boston, MA at the Joseph B. Martin Conference Center (Harvard Medical School) from June 8 to June 10.
The first poster, titled "Human Abuse Potential Study of Intranasally Administered Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Formulation" (Poster #50), summarizes data from a human abuse potential (HAP) study designed to evaluate the abuse potential and pharmacokinetics of crushed Oxycodone DETERx® administered intranasally, intact Oxycodone DETERx® administered orally, and crushed immediate-release oxycodone administered intranasally.
The second poster, titled "Abuse-Deterrent Properties of Extended-Release Oxycodone DETERx® Capsules: Non-Oral Routes of Administration" (Poster #9), summarizes data from studies covering two non-oral routes of abuse: 1) in vitro abuse-deterrent study results for Oxycodone DETERx® with respect to IV injection as a route of abuse and 2) the pharmacokinetic profiles for Oxycodone DETERx® with respect to intranasal administration as a route of abuse.
- Poster # 50: "Human Abuse Potential Study of Intranasally Administered Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Formulation"
-Date: Sunday, June 8, 2014
-Time: 8:00am to 6:00pm
-Presenter: Alison Fleming, PhD, Vice President, Product Development
- Poster # 9: "Abuse-Deterrent Properties of Extended-Release Oxycodone DETERx® Capsules: Non-Oral Routes of Administration"
-Date: Monday, June 9, 2014
-Time: 8:00am to 6:00pm
-Presenter: Alison Fleming, PhD, Vice President, Product Development
About DETERx® Technology
The DETERx® drug technology platform consists of a microsphere-in-capsule formulation. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and to administer the contents sprinkled onto food, directly into the mouth, or via a feeding tube, while maintaining the ER properties of the product. The DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® is the first of a number of product candidates using the DETERx® platform.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides ER delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.
Doug Carlson
Vice President, Corporate Development
Collegium Pharmaceutical, Inc.
781-713-3739
dcarlson@collegiumpharma.com
SOURCE: Collegium Pharmaceutical, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
Collegium_Pharma_6-5-2014_LST_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment